Effect of exercise on type 2 diabetes

The effect of concurrent training order on some mitochondrial, ribosome biogenesis regulatory myokines and insulin resistance in type 2 diabetes patient

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181002041204N1

Enrollment

Registered

2019-02-25

Start date

2018-04-09

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: The first intervention group: The aerobic-resistance group will exercise for 12 weeks and three sessions a week. The aerobic-resistance group will perform the aerobic protocol and then

Eligibility

Sex/Gender

All

Age

40 Years to 50 Years

Inclusion criteria

Inclusion criteria: Confirmation of Type 2 Diabetes (Fasting blood glucose greater than 126 mg/dL, Oral glucose tolerance test equal to or greater than 200 mg/dL, A1C level of 6.5 percent or higher) BMI 28-35 Age between 40-50 years

Exclusion criteria

Exclusion criteria: use insulin having cardiovascular diseases, musculoskeletal disorders, liver disease, kidney disease, thyroid dysfunction having regular physical activity in at least the last six months

Design outcomes

Primary

Measure	Time frame
Myostatin (MSTN). Timepoint: Before the intervention and 48 hours after the end of intervention. Method of measurement: ELISA method.;Follistatin (FSTL). Timepoint: Before the intervention and 48 hours after the end of intervention. Method of measurement: ELISA method.;Fibroblast Growth Factor 21 (FGF21). Timepoint: Before the intervention and 48 hours after the end of intervention. Method of measurement: ELISA method.;Irisin. Timepoint: Before the intervention and 48 hours after the end of intervention. Method of measurement: ELISA method.;Insulin resistance. Timepoint: Before the intervention and 48 hours after the end of intervention. Method of measurement: HOMA-IR method.;HbA1C. Timepoint: Before the intervention and 48 hours after the end of intervention. Method of measurement: Nyco Card device.	—

Measure

Time frame

Myostatin (MSTN). Timepoint: Before the intervention and 48 hours after the end of intervention. Method of measurement: ELISA method.;Follistatin (FSTL). Timepoint: Before the intervention and 48 hours after the end of intervention. Method of measurement: ELISA method.;Fibroblast Growth Factor 21 (FGF21). Timepoint: Before the intervention and 48 hours after the end of intervention. Method of measurement: ELISA method.;Irisin. Timepoint: Before the intervention and 48 hours after the end of intervention. Method of measurement: ELISA method.;Insulin resistance. Timepoint: Before the intervention and 48 hours after the end of intervention. Method of measurement: HOMA-IR method.;HbA1C. Timepoint: Before the intervention and 48 hours after the end of intervention. Method of measurement: Nyco Card device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNahid Bijeh

Ferdowsi University of Mashhad

bijeh@um.ac.ir+98 51 3880 5403

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026